BACKGROUND: To lower the number of undiagnosed infections and to improve early detection, international health agencies have promoted nontargeted human immunodeficiency virus (HIV) screening in health care settings, including emergency departments (EDs). This strategy remains controversial and has yet to be tested on a large scale. We assessed the public health impact of nontargeted HIV-rapid test (RT) screening among ED patients in the metropolitan area of Paris (11.7 million inhabitants), where half of France's new HIV cases are diagnosed annually. METHODS: During a randomly assigned 6-week period for each of the 29 participating EDs, 18- to 64-year-old patients who were able to provide consent for HIV testing were offered a fingerstick whole-blood HIV RT. Main outcome measures were the number of patients tested for HIV and their characteristics vs those of the general metropolitan Paris population and the proportion of newly diagnosed HIV-positive patients among those tested and their characteristics vs those from the national HIV case surveillance. RESULTS: Among 138,691 visits, there were 78,411 eligible patients, 20,962 of whom (27.0%) were offered HIV RT; 13,229 (63.1%) accepted testing and 12,754 (16.3%) were tested. The ED patients' characteristics reflected the general population distribution. Eighteen patients received new HIV diagnoses (0.14%; 95% confidence interval, 0.08%-0.22%). Like national HIV case surveillance patients, they belonged to a high-risk group (n = 17), were previously tested (n = 12), and were either symptomatic or had a CD4 lymphocyte count lower than 350/μL, suggesting late-stage infections (n = 8); 12 patients were linked to care. CONCLUSIONS: Nontargeted HIV testing in EDs was feasible but identified only a few new HIV diagnoses, often at late stages, and, unexpectedly, most patients belonged to a high-risk group. Our findings do not support the implementation of nontargeted screening of the general population in EDs.
RCT Entities:
BACKGROUND: To lower the number of undiagnosed infections and to improve early detection, international health agencies have promoted nontargeted human immunodeficiency virus (HIV) screening in health care settings, including emergency departments (EDs). This strategy remains controversial and has yet to be tested on a large scale. We assessed the public health impact of nontargeted HIV-rapid test (RT) screening among ED patients in the metropolitan area of Paris (11.7 million inhabitants), where half of France's new HIV cases are diagnosed annually. METHODS: During a randomly assigned 6-week period for each of the 29 participating EDs, 18- to 64-year-old patients who were able to provide consent for HIV testing were offered a fingerstick whole-blood HIV RT. Main outcome measures were the number of patients tested for HIV and their characteristics vs those of the general metropolitan Paris population and the proportion of newly diagnosed HIV-positivepatients among those tested and their characteristics vs those from the national HIV case surveillance. RESULTS: Among 138,691 visits, there were 78,411 eligible patients, 20,962 of whom (27.0%) were offered HIV RT; 13,229 (63.1%) accepted testing and 12,754 (16.3%) were tested. The ED patients' characteristics reflected the general population distribution. Eighteen patients received new HIV diagnoses (0.14%; 95% confidence interval, 0.08%-0.22%). Like national HIV case surveillance patients, they belonged to a high-risk group (n = 17), were previously tested (n = 12), and were either symptomatic or had a CD4 lymphocyte count lower than 350/μL, suggesting late-stage infections (n = 8); 12 patients were linked to care. CONCLUSIONS: Nontargeted HIV testing in EDs was feasible but identified only a few new HIV diagnoses, often at late stages, and, unexpectedly, most patients belonged to a high-risk group. Our findings do not support the implementation of nontargeted screening of the general population in EDs.
Authors: Uriel R Felsen; Chinazo O Cunningham; Moonseong Heo; Donna C Futterman; Jeffrey M Weiss; Barry S Zingman Journal: J Acquir Immune Defic Syndr Date: 2017-05-01 Impact factor: 3.731
Authors: Jason S Haukoos; Michael S Lyons; Douglas A E White; Yu-Hsiang Hsieh; Richard E Rothman Journal: Ann Emerg Med Date: 2014-08-13 Impact factor: 5.721
Authors: Roland C Merchant; Janette R Baird; Tao Liu; Lynn E Taylor; Brian T Montague; Ted D Nirenberg Journal: Acad Emerg Med Date: 2014-07 Impact factor: 3.451
Authors: Jason S Haukoos; Emily Hopkins; Meggan M Bucossi; Michael S Lyons; Richard E Rothman; Douglas A E White; Alia A Al-Tayyib; Lucy Bradley-Springer; Jonathan D Campbell; Allison L Sabel; Mark W Thrun Journal: J Acquir Immune Defic Syndr Date: 2015-04-15 Impact factor: 3.731
Authors: Jason S Haukoos; Emily Hopkins; Brooke Bender; Comilla Sasson; Alia A Al-Tayyib; Mark W Thrun Journal: Ann Emerg Med Date: 2013-01-04 Impact factor: 5.721
Authors: Jenni M Wise; Corilyn Ott; Andres Azuero; Robin Gaines Lanzi; Susan Davies; Andrea Gardner; David E Vance; Mirjam-Colette Kempf Journal: AIDS Behav Date: 2019-04